Core Points - Fangsheng Pharmaceutical announced the completion of the release of part of the pledged shares by its controlling shareholder and actual controller, Zhang Qinghua, on October 23, 2025 [2] - The number of shares released from pledge amounts to 31.58 million shares [2]

Core Viewpoint - Fangsheng Pharmaceutical announced that it has not provided guarantees for its controlling shareholders, actual controllers, or their affiliates, and there are no overdue external guarantees [2] Summary by Categories - **Company Announcement** - Fangsheng Pharmaceutical released a statement confirming that it has not provided any guarantees for its controlling shareholders and actual controllers [2] - The company also stated that there are no overdue external guarantees [2]

Core Insights - The company reported a revenue of 1.253 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 7.02% [1] - The net profit attributable to shareholders increased to 268 million yuan, showing a year-on-year growth of 17.6% [1] - The non-recurring net profit reached 213 million yuan, reflecting a year-on-year increase of 30.54% [1] - The basic earnings per share stood at 0.61 yuan [1]

Core Insights - Fangsheng Pharmaceutical reported a Q3 revenue of 419 million yuan, a year-on-year decrease of 4.26% [1] - The net profit for Q3 was 99.04 million yuan, showing a year-on-year increase of 8.49% [1] - For the first three quarters, the total revenue was 1.253 billion yuan, down 7.02% year-on-year [1] - The net profit for the first three quarters reached 268 million yuan, reflecting a year-on-year growth of 17.60% [1]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) reported a decline in revenue for the third quarter, while net profit showed an increase, indicating mixed financial performance [1] Financial Performance - The company achieved operating revenue of 419 million yuan in the third quarter, a year-on-year decrease of 4.26% [1] - Net profit attributable to shareholders was 99.04 million yuan, reflecting a year-on-year increase of 8.49% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 71.20 million yuan, representing a year-on-year growth of 36.37% [1] - Basic earnings per share were reported at 0.22 yuan [1]

Group 1 - The core viewpoint of the article is that Fangsheng Pharmaceutical reported a decline in revenue for the third quarter while achieving an increase in net profit [1] Group 2 - For the third quarter, the company's revenue was 419 million yuan, representing a year-on-year decrease of 4.26% [1] - The net profit for the third quarter was 99.04 million yuan, showing a year-on-year growth of 8.49% [1] - For the first three quarters, the total revenue was 1.253 billion yuan, which is a year-on-year decline of 7.02% [1] - The net profit for the first three quarters reached 268 million yuan, reflecting a year-on-year increase of 17.60% [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ●湖南方盛制药股份有限公司（以下简称"公司"）控股股东暨实际控制人张庆华 先生办理完成了3,158万股（占公司总股本的7.19%）公司股份解除质押手续； 证券代码：603998 证券简称：方盛制药 公告编号：2025-091 ●截至本公告披露日，张庆华先生直接持有公司的股份总数为156,019,500股，占公 司股份总数（439,081,360股）的35.53%；张庆华先生质押的公司股份总数为69,325,200 股，占其直接持有公司股份总数的44.43%，占公司股份总数的15.79%；张庆华先生控股 的湖南开舜投资咨询有限公司之控股子公司泰州共生咨询有限公司（原"泰州共生创业 投资管理有限公司"，以下简称"共生咨询"）持有公司股份数为9,131,807股，共生咨 询质押的公司股份总数为0股；张祖嵘女士持有公司股份数423,300股，张祖嵘女士质押 的公司股份 ...

说明： 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-090 湖南方盛制药股份有限公司 2025年前三季度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第六号——医药制造》的 相关规定，湖南方盛制药股份有限公司（以下简称"公司"）现 将 2025 年前三季度主要经营数据披露如下（单位：元，人民币）： | | | 主营业务分行业情况 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利 率% | 营业收 入比上 | 营业成 本比上 | 毛利率比上年增减 | | | | | | 年增减 | 年增减 | | | 工业小计 | 1,155,172,695.85 | 299,438,278.53 | 74.08 | -6.75% | 2.51% | 减少 2.34 个 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-089 湖南方盛制药股份有限公司 关于为控股子公司提供非融资性担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 担保对象及基本情况 | | 被担保人名称 | 广东方盛融华药业有限公司 | | --- | --- | --- | | | 本次担保金额 | 6,000 万元人民币 | | 担保对象 | 实际为其提供的担保余额 | 0 | | | 是否在前期预计额度内 | 是☑否□不适用：_________ | | | 本次担保是否有反担保 | 是☑否□不适用：_________ | 累计担保情况 对外担保逾期的累计金额（万元） 0 截至本公告日上市公司及其控股子公司对 外担保总额（万元人民币） 6,482.29 对外担保总额占上市公司最近一期经审计 净资产的比例（%） 3.99 特别风险提示（如有请勾选） □对外担保 ...

湖南方盛制药股份有限公司 第六届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 湖南方盛制药股份有限公司（以下简称"公司"）第六届董事会 第四次会议于 2025 年 10 月 22 日下午 15:30 在公司办公大楼一楼会议 室（一）以现场与通讯表决相结合的方式召开。公司证券部已于 2025 年 10 月 11 日以电子邮件、微信、电话等方式通知全体董事。本次会 议由董事长周晓莉女士召集并主持，会议应出席董事 6 人，实际出席 董事 6 人（独立董事高学敏先生与杜守颖女士、袁雄先生以通讯方式 参会）。本次会议参与表决人数及召集、召开程序符合《公司法》和 《公司章程》的有关规定，会议合法有效。会议审议并通过了以下议 案： 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-088 一、关于公司 2025 年第三季度报告的议案 公司审计委员会已对本议案进行事前审议，并发表了同意的意见。 公 ...